{
    "clinical_study": {
        "@rank": "137991", 
        "acronym": "MaRISS", 
        "arm_group": {
            "arm_group_label": "Mild and Rapidly Improving Ischemic Stroke"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the 90-day outcomes of mild and rapidly\n      improving ischemic stroke."
        }, 
        "brief_title": "Mild and Rapidly Improving Stroke Study", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mild or rapidly improving ischemic stroke confirmed by neuroimaging\n\n          -  Arrival to hospital within 4.5 hours of symptom onset\n\n          -  Willing to provide consent\n\n          -  Available for a telephone interview at 30 and 90 days\n\n        Exclusion Criteria:\n\n          -  Onset >4.5 hours\n\n          -  Unable to provide informed consent (patient or legally appointed representative\n\n          -  Premorbid modified Rankin Scale >1\n\n          -  Unavailable by telephone for follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with ischemic stroke defined clinically as mild and/or rapidly improving and\n        confirmed by neuroimaging not to have a hemorrhagic stroke with symptom onset within 4.5\n        hours."
            }
        }, 
        "enrollment": {
            "#text": "2650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072681", 
            "org_study_id": "20120079"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "number_of_groups": "1", 
        "official_title": "Mild and Rapidly Improving Stroke Study", 
        "overall_contact": {
            "email": "jromano@med.miami.edu", 
            "last_name": "Jose G Romano, MD", 
            "phone": "305-243-8018"
        }, 
        "overall_contact_backup": {
            "email": "icampo@med.miami.edu", 
            "last_name": "Iszet Campo-Bustillo, MD, MPH", 
            "phone": "305-243-8018"
        }, 
        "overall_official": {
            "affiliation": "University of Miami", 
            "last_name": "Jose G Romano, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is proportion of patients with a modified Rankin Scale of 2-6 at 90 days", 
            "measure": "Proportion of patients not independent at 90 days", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072681"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "Jose Romano, MD", 
            "investigator_title": "Professor of Clinical Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients not independent in activities of daily living defined as a Barthel Index score <95", 
                "measure": "Proportion of patients with dependence or disability in activities of daily living at 90 days", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Amongst those that receive intravenous Alteplase, a secondary safety measure is the proportion of patients that develop neurologic worsening development of symptomatic intracerebral hemorrhage, defined as neurological deterioration that, in the judgment of the investigator, is related to intracranial hemorrhage confirmed by CT or MRI, within 36 hours of administration of Alteplase.", 
                "measure": "Symptomatic intracranial hemorrhage due to Alteplase", 
                "safety_issue": "Yes", 
                "time_frame": "36 hours"
            }, 
            {
                "description": "Proportion of patients with modified Rankin Scale 2-6 at 30 days.", 
                "measure": "Proportion of patients not independent at 30 days", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "EuroQOL will be treated as a continuous measure", 
                "measure": "Quality of life by the EuroQOL EQ-5D", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "SIS-16 will be treated as a continuous measure", 
                "measure": "Stroke disability by the Stroke-Impact Scale-16", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "BI will be treated as a continuous measure; pre specified analysis include proportion of patients with Barthel Index <95", 
                "measure": "Independence with Activities of Daily Living by the Barthel Index", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "source": "University of Miami", 
        "sponsors": {
            "collaborator": {
                "agency": "American Heart Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Miami", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Months", 
        "verification_date": "February 2014"
    }
}